These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16699267)

  • 21. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Jansen JP; Lorch D; Langan J; Lasko B; Hermanns K; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):185-93. PubMed ID: 21292169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of peripheral opioid antagonists' new insights into opioid effects.
    Moss J; Rosow CE
    Mayo Clin Proc; 2008 Oct; 83(10):1116-30. PubMed ID: 18828971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, gender, race, or concomitant medication use.
    Senagore AJ; Bauer JJ; Du W; Techner L
    Surgery; 2007 Oct; 142(4):478-86. PubMed ID: 17950339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery.
    Delaney CP; Weese JL; Hyman NH; Bauer J; Techner L; Gabriel K; Du W; Schmidt WK; Wallin BA;
    Dis Colon Rectum; 2005 Jun; 48(6):1114-25; discussion 1125-6; author reply 1127-9. PubMed ID: 15906123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide opioid antagonist separates peripheral and central opioid antitransit effects.
    Shook JE; Pelton JT; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1987 Nov; 243(2):492-500. PubMed ID: 2824748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection.
    Wolff BG; Weese JL; Ludwig KA; Delaney CP; Stamos MJ; Michelassi F; Du W; Techner L
    J Am Coll Surg; 2007 Apr; 204(4):609-16. PubMed ID: 17382220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and physiology of opioid receptors in the gastrointestinal tract.
    Mosińska P; Zielińska M; Fichna J
    Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):3-10. PubMed ID: 26702845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacology and clinical experience with fedotozine.
    Delvaux M
    Expert Opin Investig Drugs; 2001 Jan; 10(1):97-110. PubMed ID: 11116283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of constipation in chronic pain patients].
    Shimoyama N; Shimoyama M
    Masui; 2013 Jul; 62(7):822-8. PubMed ID: 23905405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mu opioid receptor antagonists: recent developments.
    Goodman AJ; Le Bourdonnec B; Dolle RE
    ChemMedChem; 2007 Nov; 2(11):1552-70. PubMed ID: 17918759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylnaltrexone and alvimopan: economic management of opioid-induced bowel dysfunction.
    Ali SZ; Kurz A
    Expert Rev Pharmacoecon Outcomes Res; 2004 Apr; 4(2):153-7. PubMed ID: 19807518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.
    Vanderah TW; Schteingart CD; Trojnar J; Junien JL; Lai J; Riviere PJ
    J Pharmacol Exp Ther; 2004 Jul; 310(1):326-33. PubMed ID: 14993260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
    Gershon MD; Tack J
    Gastroenterology; 2007 Jan; 132(1):397-414. PubMed ID: 17241888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the peripherally selective kappa-opioid agonist, asimadoline, on adjuvant arthritis.
    Binder W; Walker JS
    Br J Pharmacol; 1998 Jun; 124(4):647-54. PubMed ID: 9690855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
    Camilleri M
    Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696
    [No Abstract]   [Full Text] [Related]  

  • 38. Opioids and the gut: pharmacology and current clinical experience.
    De Schepper HU; Cremonini F; Park MI; Camilleri M
    Neurogastroenterol Motil; 2004 Aug; 16(4):383-94. PubMed ID: 15305992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central effect of mu-opioid agonists on antral motility in conscious rats.
    Tsuchida D; Fukuda H; Koda K; Miyazaki M; Pappas TN; Takahashi T
    Brain Res; 2004 Oct; 1024(1-2):244-50. PubMed ID: 15451387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.
    Valentin N; Acosta A; Camilleri M
    Expert Opin Investig Drugs; 2015 Jun; 24(6):769-79. PubMed ID: 25971881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.